Annexon Biosciences (ANNX) PT Lowered to $24 at Needham & Company, but Analyst Reiterated "Promise in ANX007 GA Program", Sees ANX007 MoA as "Intriguing"
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer lowered the price target on Annexon Biosciences (NASDAQ: ANNX) to $24.00 (from $37.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
